Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could removing preservatives from glaucoma drops save Patients' eyes?

NCT ID NCT07690397

Ongoing Disease control Sponsor: Tecnoquimicas Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study compares two versions of a three-drug combination eye drop for glaucoma: one with preservatives and one without. Researchers want to see if the preservative-free version is gentler on the eye surface and leads to better treatment adherence. Participants will also use a chatbot for follow-up, and the study will measure changes in eye health, quality of life, and biomarkers in tears over four months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
preservative-free dorzolamide-timolol-brimonidine combination eye drops
What this could lead to
If successful, this could show that preservative-free eye drops are gentler on the eye surface and improve how consistently patients take their glaucoma medication.
What could go wrong
This is a mid-stage study with 140 participants, so results may not apply to all glaucoma patients. The chatbot follow-up is a new approach that may not improve adherence as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OCULAR HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ocular hypertension open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OCULAR HYPERTENSION PRIMARY OPEN ANGLE GLAUCOMA (POAG)

Contacts and locations

Locations

  • Clínica Sigma Cali

    Cali, Valle del Cauca Department, 760044, Colombia

More trials for these conditions

Other studies related to the condition(s) this trial covers.